MSL-HM480-100μg / 询价
MSL-HM480-500μg / 询价
MSL-HM480-500μgx2 / 询价
Human MSLN/Mesothelin Protein
Recombinant Human MSLN/Mesothelin Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Glu296-Gly580.[Accession | Q13421-2]
The protein has a predicted MW of 35.2 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human MSLN on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human MSLN was greater than 95% as determined by SEC-HPLC.
Immobilized Human MSLN, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-MSLN Antibody, hFc Tag with the EC50 of 12.4ng/ml determined by ELISA.
Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.Cloning studies showed that the mesothelin gene encodes a precursor protein that is processed to yield mesothelin which is attached to the cell membrane by a glycophosphatidylinositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor (MPF). Although it has been proposed that mesothelin may be involved in cell adhesion, its biological function is not known.A knockout mouse line that lacks mesothelin reproduces and develops normally.
MSLN; CAK1; Mesothelin; MPF; MPFSMRP; SMR
(1)Adusumilli P S , Cherkassky L , Villena-Vargas J , et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity[J]. Science Translational Medicine, 2014, 6(261):261ra151-261ra151.
(2)Morello A , Sadelain M , Adusumilli P S. Mesothelin-Targeted CARs: Driving T cells to Solid Tumors[J]. Cancer Discovery, 2015, 6(2).
